Company Encyclopedia
View More
name
Recursion Pharmaceuticals
RXRX.US
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.
1.902 T
RXRX.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking200/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-91.06%E
    • Profit Margin-1637.81%E
    • Gross Margin-2523.17%E
  • Growth ScoreD
    • Revenue YoY-32.98%E
    • Net Profit YoY-89.42%E
    • Total Assets YoY92.64%A
    • Net Assets YoY99.59%A
  • Cash ScoreD
    • Cash Flow Margin-6.11%D
    • OCF YoY-32.98%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio25.19%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)?

    Recursion Pharmaceuticals' REC-4881 trial success in reducing polyp burden in familial adenomatous polyposis patients is seen as a validation of its AI-driven drug discovery platform. This could reshape investment perceptions, highlighting potential upside despite ongoing risks like cash burn and funding needs. The company's narrative projects significant revenue and earnings by 2028, with varying fair value estimates. Investors are encouraged to explore different perspectives and consider the company's financial health and risks before making investment decisions.

    Simplywall·
    US
    RXRX
    -5.46%
    Simplywall·
    US
    RXRX
    -5.46%

    Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound

    Recursion Pharmaceuticals (RXRX) shows tentative share price rebound, with recent gains suggesting momentum. Despite a negative year-to-date return, shares are undervalued at $4.83 compared to a fair value of $6.33. Advanced AI tools are expected to enhance drug discovery, but risks include cash burn and reliance on partnerships. A DCF model suggests a fair value of $4.36, indicating slight overvaluation. Investors are encouraged to explore healthcare stocks and use targeted screeners for undervalued opportunities.

    Simplywall·
    US
    RXRX
    -5.46%
    Simplywall·
    US
    RXRX
    -5.46%

    Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals

    Analyst Gil Blum from Needham reiterated a Buy rating for Recursion Pharmaceuticals, citing promising clinical study results and an upcoming FDA meeting. The Phase Ib/2 TUPELO study showed 75% of patients experienced a reduction in polyps, indicating potential success for REC-4881. The treatment's durability and manageable toxicities further support the Buy rating. Blum, a 4-star analyst, has a $8.00 price target for the stock.

    Tip Ranks·
    US
    RXRX
    -5.46%
    Tip Ranks·
    US
    RXRX
    -5.46%

    Recursion shares are trading higher after the company reported Phase 1b/2 TUPELO results showing REC-4881 reduced polyp burden in FAP, supporting plans for FDA engagement in 1H26.

    benzinga_article·
    US
    RXRX
    -5.46%
    benzinga_article·
    US
    RXRX
    -5.46%

    Pre-market hot trades in US stocks: AI technology aids drug development, Recursion rises 9.13% in pre-market, market confidence offsets the impact of executive sell-offs

    Recursion Pharmaceuticals rose 9.13% in pre-market; Cemtrex rose 302.28% in pre-market; Treasure Gbl rose 125.90% in pre-market; Biodexa Pharmaceuticals rose 96.43% in pre-market

    Tracking Unusual Activity·
    US
    RXRX
    -5.46%
    Tracking Unusual Activity·
    US
    RXRX
    -5.46%
    Posts
    View More

    $Recursion Pharmaceuticals(RXRX.US) The momentum is still a bit lacking. Institutions need to step up their efforts;

    $Recursion Pharmaceuticals(RXRX.US)Here it comes, here it comes, come on!

    $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

    $Recursion Pharmaceuticals(RXRX.US) is rising well, give me some more strength. Still bullish.

    Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Pa......

    • 0
    © 2025 Longbridge｜Disclaimer